Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 177-183 , February 2008

Ex vivo evaluation of N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-fluorophenyl)nortropane in rats

  • Teija Koivula

      Affiliations

    • Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
    • ,
  • Päivi Marjamäki

      Affiliations

    • MediCity PET Laboratory, Turku PET Centre, Tykistökatu 6 A, FI-20520 Turku, Finland
    • ,
  • Merja Haaparanta

      Affiliations

    • MediCity PET Laboratory, Turku PET Centre, Tykistökatu 6 A, FI-20520 Turku, Finland
    • ,
  • Veronica Fagerholm

      Affiliations

    • MediCity PET Laboratory, Turku PET Centre, Tykistökatu 6 A, FI-20520 Turku, Finland
    • ,
  • Tove Grönroos

      Affiliations

    • MediCity PET Laboratory, Turku PET Centre, Tykistökatu 6 A, FI-20520 Turku, Finland
    • ,
  • Tiina Lipponen

      Affiliations

    • Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
    • ,
  • Outi Perhola

      Affiliations

    • Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
    • ,
  • Jouko Vepsäläinen

      Affiliations

    • Department of Chemistry, University of Kuopio, P.O. Box 1627, FI-70210 Kuopio, Finland
    • ,
  • Olof Solin

      Affiliations

    • Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
    • MediCity PET Laboratory, Turku PET Centre, Tykistökatu 6 A, FI-20520 Turku, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 2 3132851; fax: +358 2 2818191.

Received 11 September 2007 ,Accepted 27 September 2007.

References 

  1. Bannon MJ, Granneman JG, Kapatos G. The dopamine transporter: potential involvement in neuropsychiatric disorders. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: the fourth generation of progress. New York: Raven Press, Ltd; 1995;p. 179–188
  2. Hoffman BJ, Hansson SR, Mezey É, Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol. 1998;19:187–231
  3. Masson J, Sagné C, Hamon M, El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol Rev. 1999;51:439–464
  4. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci. 2003;4:13–25
  5. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 1996;16:436–447
  6. Nirenberg MJ, Chan J, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J Neurosci. 1997;17:5255–5262
  7. Nirenberg MJ, Chan J, Pohorille A, Vaughan RA, Uhl GR, Kuhar MJ, et al. The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J Neurosci. 1997;17:6899–6907
  8. Laakso A, Hietala J. PET studies of brain monoamine transporters. Curr Pharm Des. 2000;6:1611–1623
  9. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204:355–360
  10. Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [18F]β-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:737–741
  11. Clarke RL, Daum SJ, Gambino AJ, Aceto MD, Pearl J, Levitt M, et al. Compounds affecting the central nervous system: 4. 3β-Phenyltropane-2-carboxylic esters and analogs. J Med Chem. 1973;16:1260–1267
  12. Carroll FI, Lewin AH, Boja JW, Kuhar MJ. Cocaine receptor: biochemical characterization and structure–activity relationships of cocaine analogues at the dopamine transporter. J Med Chem. 1992;35:969–981
  13. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse. 1993;15:130–142
  14. Haaparanta M, Bergman J, Laakso A, Hietala J, Solin O. [18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats. Synapse. 1996;23:321–327
  15. Xing D, Chen P, Keil R, Kilts CD, Shi B, Camp VM, et al. Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2β-carbo-1′-fluoro-2-propoxy-3β-(4-chlorophenyl)tropanes. Ligands for the imaging of dopamine transporters by positron emission tomography. J Med Chem. 2000;43:639–648
  16. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy-3β-(3′,4′-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40:1366–1372
  17. Müller L, Halldin C, Farde L, Karlsson P, Hall H, Swahn CG, et al. [11C]β-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. Nucl Med Biol. 1993;20:249–255
  18. Farde L, Halldin C, Müller L, Suhara T, Karlsson P, Hall H. PET study of [11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse. 1994;16:93–103
  19. Lundkvist C, Halldin C, Swahn C-G, Hall H, Karlsson P, Nakashima Y, et al. [O-Methyl-11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol. 1995;22:905–913
  20. Lundkvist C, Halldin C, Ginovart N, Swahn C-G, Farde L. [18F]β-CIT-FP is superior to [11C]β-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol. 1997;24:621–627
  21. Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, et al. Radiosynthesis of [18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane and the first human study with positron emission tomography. Nucl Med Biol. 1996;23:999–1004
  22. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521–1530
  23. Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, et al. 18F-Labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol. 2000;27:1–12
  24. Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44:855–861
  25. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Hietala J. [18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse. 1998;28:244–250
  26. Harada N, Ohba H, Fukumoto D, Kakiuchi T, Tsukada H. Potential of [18F]β-CFT-FE (2β-carbomethoxy-3β-(4-fluorophenyl)-8-(2-[18F]fluoroethyl)nortropane) as a dopamine transporter ligand: a PET study in the conscious monkey brain. Synapse. 2004;54:37–45
  27. Firnau G, Chen JJ, Murthy D. N-[18F]fluoroalkyl-CFT: synthesis and cerebral distribution. J Label Compd Radiopharm. 1995;37:55–57
  28. Kämäräinen E-L, Kyllönen T, Airaksinen A, Lundkvist C, Yu M, Någren K, et al. Preparation of [18F]β-CFT-FP and [11C]β-CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET). J Label Compd Radiopharm. 2000;43:1235–1244
  29. Kämäräinen E-L, Kyllönen T, Lundkvist C, Hall H, Bergström K, Yu M, et al. Labeling of the dopamine transporter ligand β-CFT-FP with 18F or 11C. J Label Compd Radiopharm. 1999;42(Suppl 1):S414–S416
  30. Kämäräinen E-L, Kyllönen T, Hall H, Lundkvist C, Bergström K, Yu M, et al. Autoradiographic examination of a new dopamine transporter radioligand, carbon-11 β-CFT-FP, in the post mortem human brain. Eur J Nucl Med. 2000;27:1221
  31. Koivula T, Perhola O, Kämäräinen E-L, Lipponen T, Vepsäläinen J, Solin O. Simplified synthesis of N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-fluorophenyl)nortropane ([18F]β-CFT-FP) using [18F]fluoropropyl tosylate as the labelling reagent. J Label Compd Radiopharm. 2005;48:463–471
  32. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic Press; 1986;
  33. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001;91:35–62
  34. Goodman MM, Keil R, Shoup TM, Eshima D, Eshima L, Kilts C, et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med. 1997;38:119–126
  35. Mach RH, Nader MA, Ehrenkaufer RL, Gage HD, Childers SR, Hodges LM, et al. Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. Synapse. 2000;37:109–117
  36. Heikkila RE, Manzino L. Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol. 1984;103:241–248
  37. Andersen PH. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol. 1989;166:493–504
  38. D'Amato RJ, Largent BL, Snowman AM, Snyder SH. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther. 1987;242:364–371
  39. Sur C, Betz H, Schloss P. Immunocytochemical detection of the serotonin transporter in rat brain. Neuroscience. 1996;73:217–231
  40. Lorang D, Amara SG, Simerly RB. Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci. 1994;14:4903–4914
  41. Burchett SA, Bannon MJ. Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to ‘binge’ cocaine administration. Mol Brain Res. 1997;49:95–102
  42. Miller GM, Yatin SM, De La Garza R, Goulet M, Madras BK. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Mol Brain Res. 2001;87:124–143
  43. VanNess SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 2005;6:55
  44. Husbands SM, Izenwasser S, Loeloff RJ, Katz JL, Bowen WD, Vilner BJ, et al. Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]-carbazole (Rimcazole): irreversible ligands for the dopamine transporter. J Med Chem. 1997;40:4340–4346
  45. Reith MEA, Coffey LL. Cationic and anionic requirements for the binding of 2β-carbomethoxy-3β-(4-fluorophenyl) [3H]tropane to the dopamine uptake carrier. J Neurochem. 1993;61:167–177
  46. Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. Cocaine receptors labeled by [3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol. 1989;36:518–524
  47. Kemppainen N, Marjamäki P, Röyttä M, Rinne J. Different pattern of reduction of striatal dopamine reuptake sites in Alzheimer's disease and ageing. J Neural Transm. 2001;108:827–836
  48. Allard PO, Rinne J, Marcusson JO. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res. 1994;637:262–266
  49. Lee S-H, Chang M-Y, Jeon D-J, Oh D-Y, Son H, Lee C-H, et al. The functional domains of dopamine transporter for cocaine analog, CFT binding. Exp Mol Med. 2002;34:90–94

PII: S0969-8051(07)00245-4

doi: 10.1016/j.nucmedbio.2007.09.006

Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 177-183 , February 2008

Article Tools

* Image Usage & Resolution